Antigen's modified cancer vaccine moves forward with IND filing
This article was originally published in Scrip
Antigen Express, a subsidiary of Generex Biotechnology, has announced that a physician-sponsored IND has been submitted to the US FDA for its modified immunotherapeutic cancer vaccine, AE37 combined with a vaccine peptide, to enable a Phase I trial in breast and ovarian cancer to start.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.